Table 2. Univariate and univariate analyses to determine predictors related to csPCa.
| Characteristics | Univariate regression analysis | Multivariate regression analysis | |||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | P value | OR | 95% CI | P value | ||
| Age (years) | 1.08 | 1.02–1.15 | 0.008 | 0.99 | 0.90–1.10 | 0.917 | |
| BMI (kg/m2) | 1.04 | 0.90–1.21 | 0.609 | ||||
| tPSA (ng/mL) | 1.12 | 1.06–1.17 | <0.001 | 1.06 | 0.94–1.19 | 0.330 | |
| Hypertension | 1.56 | 0.68–3.61 | 0.297 | ||||
| Diabetes | 1.21 | 0.34–4.32 | 0.773 | ||||
| CHD | 0.32 | 0.04–2.68 | 0.292 | ||||
| Smoking | 1.20 | 0.53–2.71 | 0.662 | ||||
| Drinking | 1.70 | 0.75–3.86 | 0.205 | ||||
| Prostate volume (mL) | 0.99 | 0.97–1.00 | 0.117 | ||||
| PSAd (ng/mL2) | 118.14 | 15.06–926.73 | <0.001 | 1.40 | 0.03–57.55 | 0.860 | |
| PI-RADS 4 vs. PI-RADS≤3 | 8.00 | 2.22–28.77 | 0.001 | 6.02 | 1.11–32.49 | 0.037 | |
| PI-RADS 5 vs. PI-RADS≤3 | 30.48 | 9.18–101.23 | <0.001 | 8.34 | 1.84–37.90 | 0.006 | |
| SUVmax | 1.34 | 1.18–1.51 | <0.001 | 1.28 | 1.11–1.47 | <0.001 | |
OR, odds ratio; CI, confidence interval; BMI, Body mass index; tPSA, total prostate-specific antigen; CHD, coronary heart disease; PSAd, prostate-specific antigen density; PI-RADS, Prostate Imaging Reporting and Data System; SUVmax, maximum standard uptake value.